WASHINGTON (Reuters) – Philip Morris International Inc should not be allowed to claim that its iQOS electronic tobacco device can reduce the risk of tobacco-related diseases compared with cigarettes, an advisory panel to the U.S. Food and Drug Administration said on Thursday.
Latest posts by Reuters News (see all)
- Germany plans to lower threshold for probes of foreign takeovers: Handelsblatt - December 16, 2018
- Damascus prepares for Christmas without mortar fire - December 16, 2018
- Qatar Petroleum to invest $20 billion in U.S. in major expansion - December 16, 2018